Abstract
Background
Several studies have compared the survival rate of melanoma of unknown primary (MUP) patients with patients with a known primary melanoma (MKP). Some studies found improved survival in MUP patients, whereas others found similar or poorer outcomes. The aim of this study was to evaluate if there was a difference in survival between patients with MUP and patients with a MKP with stage III and IV disease.
Methods
A retrospective study was conducted of 48 MUP patients and 502 MKP patients diagnosed with American Joint Committee on Cancer (AJCC) stage III and 92 MUP patients and 218 MKP patients diagnosed with AJCC stage IV melanoma at Aarhus University Hospital and Odense University Hospital, Denmark, between 2003 and 2013.
Results
Multivariate analysis of data identified no significant survival differences between MUP and MKP patients with stage III (hazard ratio [HR] = 0.84; P = 0.46) and stage IV (hazard ratio [HR] = 1.03; P = 0.84) disease.
Conclusions
This study included patients from two major university hospitals in Denmark and showed no difference in overall survival between MUP and MKP patients with stage III or IV disease.
Level of Evidence: Level IV, risk/prognostic study.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kræftens Bekæmpelse. Available from https://www.cancer.dk/modermaerkekraeft-malignt-melanom/kort-om-modermaerkekraeft/. Accessed 2 Aug 2016
Shenoy BV, Fort L, Benjamin SP (1987) Malignant melanoma primary in lymph node: the case of the missing link. Am J Surg Pathol 11:140–146
Giuliano AE, Moseley HS, Morton DL (1980) Clinical aspects of unknown primary melanoma. Ann Surg 191:98–104
Kalialis LV, Drzewiecki KT, Klyver H (2009) Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res 19:275–282
Chang AE, Karnell LH, Menck HR (1998) The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade–the American College of Surgeons Commision on cancer and the American Cancer Society. Cancer 83:1664–1678
Katz KA, Jonasch E, Hodi FS et al (2005) Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res 15:77–82
Pfeil AF, Leiter U, Buettner PG et al (2011) Melanoma of unknown primary is correctly classified by the AJCC melanoma classification from 2009. Melanoma Res 21:228–234
Lopez R, Holyoke ED, Moore RH et al (1982) Malignant melanoma with unknown primary site. J Surg Oncol 19:151–154
Chang P, Knapper WH (1982) Metastatic melanoma of unknown primary. Cancer 49:1106–1111
Anbari KK, Schuchter LM, Bucky LP et al (1997) Melanoma of unknown primary site: presentation, treatment, and prognosis–a single institution study. University of Pennsylvania Pigmented Lesion Study Group. Cancer 79:1816–1821
Lee CC, Faries MB, Wanek LA et al (2008) Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol 26:535–541
Lee CC, Faries MB, Wanek LA et al (2008) Improved survival for stage IV melanoma from an unknown primary melanoma. J Clin Oncol 27:3489–3495
Schlagenhauff B, Stroebel W, Ellwanger U et al (1997) Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: recommendations for initial staging examinations. Cancer 80:60–65
Pack GT, Gerber DM, Scharngel IM (1952) End results in the treatment of malignant melanoma: a report of 1190 cases. Ann Surg 136:905–991
Cormier JN, Xing Y, Feng L et al (2006) Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer 106:2012–2020
Prens SP, Ploeg APT, Akkoi ACJ et al (2011) Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site. Ann Surg Oncol 18:3586–3592
Ribero S, Pampena R, Bataille V et al (2017) Unknown primary. Worldwide survey on clinical management. Dermatology, Melanoma. https://doi.org/10.1159/000453592
Maio M (2012) Melanoma as a model tumour for immuno-oncology. Ann Oncol 23:10–14
Wenzel J, Bekisch B, Uerlich M et al (2005) Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions. Am J Clin Pathol 124:37–48
Morton DL, Malmgren RA, Holmes EC et al (1968) Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery 64:233–240
Litvak DA, Gupta RK, Yee R et al (2004) Endogenous immune response to early- and intermediate- stage melanoma is correlated with outcomes and is independent of locoregional relapse and standard prognostic factors. J Am Coll Surg 198:27–35
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
None.
Conflict of interest
Jes Christian Rødgaard, Ulrik Kjerkegaard, Jens Ahm Sørensen, and Lars Bjørn Stolle declare that they have no conflict of interest.
Ethical approval
Ethical approval is not required for a retrospective register study.
Informed consent
For this type of study, formal consent is not required.
Rights and permissions
About this article
Cite this article
Rødgaard, J.C., Kjerkegaard, U., Sørensen, J.A. et al. Do melanoma patients with melanoma of unknown primary have better survival than patients with melanoma of known primary?. Eur J Plast Surg 41, 229–232 (2018). https://doi.org/10.1007/s00238-017-1363-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00238-017-1363-2